H-Ile-OHCAS# 73-32-5 |
- D-allo-Ile-OH
Catalog No.:BCC2966
CAS No.:1509-35-9
- H-D-Allo-Ile-OH
Catalog No.:BCC2683
CAS No.:319-78-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 73-32-5 | SDF | Download SDF |
| PubChem ID | 6306 | Appearance | Powder |
| Formula | C6H13NO2 | M.Wt | 131.2 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Isoleucine | ||
| Solubility | H2O : 25 mg/mL (190.59 mM; Need ultrasonic) | ||
| Chemical Name | (2S,3S)-2-amino-3-methylpentanoic acid | ||
| SMILES | CCC(C)C(C(=O)O)N | ||
| Standard InChIKey | AGPKZVBTJJNPAG-WHFBIAKZSA-N | ||
| Standard InChI | InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
H-Ile-OH Dilution Calculator
H-Ile-OH Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 7.622 mL | 38.1098 mL | 76.2195 mL | 152.439 mL | 190.5488 mL |
| 5 mM | 1.5244 mL | 7.622 mL | 15.2439 mL | 30.4878 mL | 38.1098 mL |
| 10 mM | 0.7622 mL | 3.811 mL | 7.622 mL | 15.2439 mL | 19.0549 mL |
| 50 mM | 0.1524 mL | 0.7622 mL | 1.5244 mL | 3.0488 mL | 3.811 mL |
| 100 mM | 0.0762 mL | 0.3811 mL | 0.7622 mL | 1.5244 mL | 1.9055 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
H-Ile-OH
- Melatonin
Catalog No.:BCN2196
CAS No.:73-31-4
- Adenine
Catalog No.:BCC4450
CAS No.:73-24-5
- H-Trp-OH
Catalog No.:BCC3111
CAS No.:73-22-3
- Cordycepin
Catalog No.:BCN5389
CAS No.:73-03-0
- L-(-)-threo-3-Hydroxyaspartic acid
Catalog No.:BCC6565
CAS No.:7298-99-9
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
- BMS-707035
Catalog No.:BCC2133
CAS No.:729607-74-3
- XRP44X
Catalog No.:BCC7568
CAS No.:729605-21-4
- Gomisin O
Catalog No.:BCN2875
CAS No.:72960-22-6
- Gomisin E
Catalog No.:BCN7031
CAS No.:72960-21-5
- 6,7-Dihydroneridienone A
Catalog No.:BCN4020
CAS No.:72959-46-7
- 2-Furoyl-LIGRLO-amide
Catalog No.:BCC3958
CAS No.:729589-58-6
- Guanine
Catalog No.:BCN8414
CAS No.:73-40-5
- Lidocaine hydrochloride
Catalog No.:BCC9009
CAS No.:73-78-9
- 15-Isopimarene-8,18-diol
Catalog No.:BCN4287
CAS No.:73002-86-5
- CyPPA
Catalog No.:BCC7526
CAS No.:73029-73-9
- Atractylenolide III
Catalog No.:BCN1045
CAS No.:73030-71-4
- Epigomisin O
Catalog No.:BCN2862
CAS No.:73036-31-4
- Atractylenolide I
Catalog No.:BCN1043
CAS No.:73069-13-3
- Atractylenolide II
Catalog No.:BCN1044
CAS No.:73069-14-4
- Praeruptorin A
Catalog No.:BCN4987
CAS No.:73069-25-7
- (+)-Praeruptorin A
Catalog No.:BCN4989
CAS No.:73069-27-9
- Praeruptorin D
Catalog No.:BCN4990
CAS No.:73069-28-0
- Scutebarbatine D
Catalog No.:BCN8536
CAS No.:910099-76-2
Arginase enzymes in the human prostate: expression of arginase isoenzymes and effects of arginase inhibitors on isolated human prostate tissue.[Pubmed:23017122]
BJU Int. 2012 Dec;110(11 Pt C):E1196-201.
UNLABELLED: What's known on the subject? and What does the study add? A previous study by Lexander et al. in 2005, using two-dimensional gel electrophoresis, demonstrated the expression of arginase type II in the different anatomical regions of the prostate; however, to date, no study has addressed, using an in vitro approach, the role of arginase isoenzymes in the human prostate. The results of the present study demonstrate that: both arginase isoenzymes, Arg I and Arg II, are expressed in the transition zone of the human prostate; the inhibition of arginase antagonized, to a certain degree, the tension brought about by noradrenaline in isolated human prostate tissue; exposure of human prostate tissue to arginase inhibitors enhanced the local production of cyclic GMP; and inhibition of arginase enzymes in the human prostate may augment the activity of the nitric oxide/cyclicGMP pathway. OBJECTIVE: * To investigate the expression of arginase isoenzymes type I (Arg I) and type II (Arg II) in the transition zone of the human prostate and the functional significance of arginase enzymes in the control of prostate smooth muscle. MATERIALS AND METHODS: * Human prostate tissue was obtained from male patients who had undergone pelvic surgery. * The expression of Arg I and Arg II was investigated using Western blot analysis. * Using the organ bath technique, the effects of cumulative administration of difluoromethylornithine (DFMO), H-Orn-OH x HCl, H-Ile-OH and N-omega-hydroxy-nor-L-arginine (nor-NOHA; 1 nM-10 microM) on the tension induced by noradrenaline in isolated prostate tissue were assessed. * Tissue strips were also exposed to arginase inhibitors and the production of cyclic GMP was determined. RESULTS: * Western blot analysis showed the expression of Arg I and Arg II in the transition zone of the prostate. * The tension induced by noradrenaline was antagonized by the drugs in the following rank order of efficacy: H-Orn-OH x HCl >/= H-Ile-OH >/= DFMO > nor-NOHA; however, the maximum reversion of tension recorded ranged from only -25 to -13%. * The enhancement in cyclic GMP production registered in the presence of the arginase inhibitors ranged from four- to 14-fold. CONCLUSIONS: * Arg I and Arg II are expressed in the transition zone of the human prostate. * Isometric tension studies and measurement of cyclic GMP showed that inhibition of arginase can reverse, to a certain degree, the tension of human prostate tissue induced by the activation of alpha-adrenoceptors and enhance the accumulation of cyclic GMP. * Future studies should explore further the role of arginase enzymes in the relaxation mediated by nitric oxide in prostate smooth muscle.
